Faeth Therapeutics
FTH
20 hedge funds and large institutions have $760K invested in Faeth Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0.09% less ownership
Funds ownership: 0.47% → 0.38% (-0.09%)
13% less funds holding
Funds holding: 23 → 20 (-3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
34% less capital invested
Capital invested by funds: $1.16M → $760K (-$398K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$20.2K |
| 2 |
Renaissance Technologies
New York
|
+$9.75K |
| 3 |
Barclays
London,
United Kingdom
|
+$1.22K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$865 |
| 5 |
Citigroup
New York
|
+$57 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$95.1K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$30.8K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$30.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28.3K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$23.5K |
FTH Hedge Fund Activity: Q1 2025 in Review
20 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2025, worth a combined $760K — down 34% from $1.16M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of FTH and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, opening a new position worth an estimated $20.2K. The largest seller was Ikarian Capital, cutting an estimated $95.1K.
- 20 institutional investors held Faeth Therapeutics (FTH) as of Q1 2025, down from 23 in Q4 2024.
- Funds reported $760K of Faeth Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
- 3 funds opened new Faeth Therapeutics positions in Q1 2025 and 6 closed out, a net change of -3 holders.
- The largest Faeth Therapeutics buyer in Q1 2025 was UBS Group, an estimated $20.2K added.
- The largest Faeth Therapeutics seller in Q1 2025 was Ikarian Capital, an estimated $95.1K sold.
Based on aggregated 13F filings for Q1 2025.